Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

February 1, 2024

https://www.globenewswire.com/news-release/2023/03/14/2627212/0/en/Bellicum-Discontinues-Phase-1-2-Trials-and-Initiates-Evaluation-of-Strategic-Alternatives.html

HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid.

Read more at globenewswire.com

Related news for (BLCM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.